Patents Assigned to Astellas Pharma Inc.
-
Publication number: 20230202096Abstract: Provided is a fast-eluting three-dimensionally molded object, which is formed by fused deposition modeling type three-dimensional molding and quickly elutes an active component. The fast-eluting three-dimensionally molded object is formed by the fused deposition modeling type three-dimensional molding and includes an active component, a water-soluble thermoplastic polymer, a water-soluble sugar and/or a water-soluble sugar alcohol, and a plasticizer component. The fast-eluting three-dimensionally molded object has an elution rate of the active component of 80% or higher within 85 minutes by a dissolution test method in the Japanese Pharmacopoeia, Sixteenth Edition.Type: ApplicationFiled: February 23, 2023Publication date: June 29, 2023Applicant: ASTELLAS PHARMA INC.Inventors: Sorato Ikeda, Shota Hattori, Masanori Kobayashi
-
Patent number: 11679166Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.Type: GrantFiled: November 12, 2019Date of Patent: June 20, 2023Assignee: Astellas Pharma Inc.Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
-
Patent number: 11672851Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.Type: GrantFiled: December 1, 2020Date of Patent: June 13, 2023Assignees: RIKEN, ASTELLAS PHARMA INC.Inventors: Ayaka Akiba, Tatsuya Okudaira, Yasuhide Masuhara, Keisuke Ohsumi, Shinichiro Fujii
-
Patent number: 11667724Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.Type: GrantFiled: July 6, 2018Date of Patent: June 6, 2023Assignee: ASTELLAS PHARMA INC.Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
-
Publication number: 20230157946Abstract: Provided is a pharmaceutical composition that can be administered into the ear without any complicated operation and has a function of allowing a drug to be retained and slowly released in the ear. A pharmaceutical composition for otic administration, comprising one, or two or more drugs and a polymer, wherein when the complex viscosity of the pharmaceutical composition is measured using a rheometer under the conditions of a shear strain of 5% and an angular frequency of 50 rad/sec., while increasing the temperature from 25° C. to 37° C. at a heating rate of 1° C./10 sec., the complex viscosity is less than 1,650 mPa·s at 25° C., and is from 1,650 mPa·s to 100,000 mPa·s at 10 minutes after reaching 37° C.Type: ApplicationFiled: July 30, 2020Publication date: May 25, 2023Applicant: Astellas Pharma Inc.Inventors: Takatsune YOSHIDA, Mari OSADA, Takaya MATSUDA, Ken SHIMADA, Hiroyuki KOJIMA, Akira NAGAKURA
-
Patent number: 11638730Abstract: The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.Type: GrantFiled: September 25, 2019Date of Patent: May 2, 2023Assignee: Astellas Pharma Inc.Inventors: Shinsuke Nakao, Tatsuya Kawase
-
Publication number: 20230113105Abstract: A detection unit (88) detects a specific state of a wearer. A signal communication unit (92) wirelessly transmits, to an information processing apparatus, log information indicating a detection result obtained by the detection unit (88) detecting the specific state and a date and time when the specific state is detected. A stimulus application unit (94) applies a stimulus to the wearer when the specific state is detected by the detection unit (88).Type: ApplicationFiled: February 26, 2021Publication date: April 13, 2023Applicant: Astellas Pharma Inc.Inventors: Toshiaki AOKI, Yuko NAKAO, Ryugo ENOMOTO, Akiko HARAGUCHI
-
Publication number: 20230111840Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.Type: ApplicationFiled: December 7, 2022Publication date: April 13, 2023Applicants: Kyoto University, Astellas Pharma Inc.Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI
-
Patent number: 11617790Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.Type: GrantFiled: December 1, 2020Date of Patent: April 4, 2023Assignees: Astellas Pharma Inc., RIKENInventors: Keisuke Ohsumi, Taku Yoshida, Masayuki Kanki, Shinichiro Fujii, Kanako Shimizu
-
Publication number: 20230059753Abstract: Object: To provide an antisense guide RNA for editing a target RNA by ADAR. Solution: An antisense guide RNA for editing a target RNA by ADAR, containing at least one functional region and an antisense region that is complementary to a portion of the target RNA and can form a double strand with the target RNA, in which the at least one functional region is linked to the antisense region, and in which the guide RNA does not substantially contain an ADAR-recruiting base sequence.Type: ApplicationFiled: December 8, 2020Publication date: February 23, 2023Applicant: Astellas Pharma Inc.Inventors: Eiji YOSHIMI, Yukari MORIYA, Mariko MANDA, Takayasu GOTOH, Takatomo ARAI
-
Patent number: 11578067Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.Type: GrantFiled: January 30, 2018Date of Patent: February 14, 2023Assignees: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.Inventors: Shimon Sakaguchi, Naganari Ohkura, Norihisa Mikami, Shuh Narumiya, Masahiko Akamatsu, Guliang Xia, Hironori Harada, Naoto Nakamura, Satoru Ujihara, Hisao Hamaguchi
-
Publication number: 20230000965Abstract: An object of the present invention is to provide clinically applicable aAVC-NY-ESO-1 cells stably expressing NY-ESO-1 in order to use aAVC-NY-ESO-1 cells in treating patients having a NY-ESO-1-expressing cancer. The present invention provides, for example, a human-derived cell comprising a polynucleotide encoding CD1d and a polynucleotide encoding NY-ESO-1 or a fragment thereof, wherein the polynucleotide encoding NY-ESO-1 or a fragment thereof is operably linked to an inducible promoter.Type: ApplicationFiled: December 1, 2020Publication date: January 5, 2023Applicants: ASTELLAS PHARMA INC., RIKENInventors: Ayaka AKIBA, Tatsuya OKUDAIRA, Yasuhide MASUHARA, Keisuke OHSUMI, Shinichiro FUJII
-
Patent number: 11541127Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: April 13, 2016Date of Patent: January 3, 2023Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
-
Publication number: 20220379171Abstract: An exercise support device (10) includes: an acquisition unit (11A) that acquires a physical quantity indicating an execution degree of an exercise according to an exercise program indicating a predetermined self-weight exercise; a deriving unit (11B) that derives subsequent intensity of the exercise by using the physical quantity acquired by the acquisition unit (11A); and a presentation unit (11C) that presents the intensity derived by the deriving unit (11B).Type: ApplicationFiled: October 20, 2020Publication date: December 1, 2022Applicant: Astellas Pharma Inc.Inventor: Motohiro KANAYAMA
-
Publication number: 20220356207Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.Type: ApplicationFiled: June 30, 2022Publication date: November 10, 2022Applicants: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima UniversityInventors: Hideki ENDO, Yukihito ISHIZAKA, Akira ISHIGURO, Tomoki TAKASHINA, Takashi YAMAMOTO, Tetsushi SAKUMA
-
Patent number: 11473071Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.Type: GrantFiled: May 14, 2021Date of Patent: October 18, 2022Assignees: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATIONInventors: Eiji Yoshimi, Katsuro Yoshioka, Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Nidhi Khanna
-
Publication number: 20220275359Abstract: [Problem to be Solved] To provide a guide RNA. [Solution] A guide RNA for editing a target RNA sequence, comprising an antisense nucleotide sequence complementary to a portion of the target RNA sequence, a short-chain ADAR-recruiting nucleotide sequence, and at least one functional nucleotide sequence.Type: ApplicationFiled: July 31, 2020Publication date: September 1, 2022Applicants: Astellas Pharma Inc., Fukuoka UniversityInventors: Eiji YOSHIMI, Yukari MORIYA, Mariko MANDA, Masatora FUKUDA
-
Patent number: 11414456Abstract: The present application provides a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.Type: GrantFiled: December 10, 2018Date of Patent: August 16, 2022Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima UniversityInventors: Hideki Endo, Yukihito Ishizaka, Akira Ishiguro, Tomoki Takashina, Takashi Yamamoto, Tetsushi Sakuma
-
Publication number: 20220233721Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcriptional repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 127, SEQ ID NO: 46, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 137, SEQ ID NO: 117, or SEQ ID NO: 119 in an expression regulatory region of a human DMPK gene, are expected to be useful for treating muscular dystrophy.Type: ApplicationFiled: May 27, 2020Publication date: July 28, 2022Applicants: Astellas Pharma Inc., Modalis Therapeutics CorporationInventors: Eiji YOSHIMI, Tomoya OE, Tetsuya YAMAGATA, Keith M. CONNOLLY
-
Patent number: 11395852Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.Type: GrantFiled: October 11, 2018Date of Patent: July 26, 2022Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Ugur Sahin, Özlem Türeci